23andme, a consort that helps consumers see and read their genomes, has upraised a coloured $11 meg discover of a $24.26 meg B ammo of funding, according to regulatory filings. 23andme, which was co-founded by Google co-founder Sergey Brin’s wife, Anne Wojcicki, upraised $9 meg in Series A resource from Google, Genentech, New Enterprise Associates, and Mohr Davidow Ventures in 2007.

Now PEHub is reporting that Mohr Davidow Ventures divested its wager in 23andme after finance in a candid competitor Navigenics. Losing digit of your important investors to a competitor is not a beatific sign. 23andme maps customers? polymer and helps them encounter aggregation most their derivation and their risks of effort destined diseases (Michael tried it terminal year). Google ended up attractive a $3.9 meg stake in 23andMe in May 2007, after Brin had personally loaned the consort $2.6 million. The debt was repaid after the Google investment. We’re peculiar as to how much, if any, of this round’s $11 meg is Brin’s or Google’s money.

Also, we’d same to undergo ground Mohr Davidow shifted its assets to a 23andme’s rival. Navigenics’ assist is kindred to 23andme’s with offense differences. For example, 23andme offers digit package, priced at $399, to effort your saliva. Navigenics offers digit packages of investigating priced at at $499 and $2,499, with the higher priced effort including transmitted counseling and investigating for more upbeat conditions. Most recently, California?s Department of Public Health issued cease and desist letters to 23andMe, Navigenics and 11 another transmitted investigating startups, mandating that the labs shew that they hit been certificated by both the land and federal government, and, perhaps more importantly, that every transmitted tests were sequential by a patient?s doctor, which is required by land law.

Crunch Network: MobileCrunch Mobile Gadgets and Applications, Delivered Daily.